BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioTech Medics, Inc. (BTMD) Signs $5 Million Cross-Marketing Licensing Agreement With LifeBionix, Inc.


7/1/2013 12:19:20 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

IRVING, TX--(Marketwired - July 01, 2013) -

BioTech Medics, Inc., (PINKSHEETS: BMCS) announced that it has signed a $5 million U.S. cross-marketing licensing non-exclusive contract for its patented SHBAN Alcohol Free Persistent Hand & Body Sanitizer with LifeBionix, Inc. The agreement includes cash and ongoing royalties payable to BioTech over a five year term anticipated to start third quarter 2013 without dilution of BioTech stock.

LifeBionix is a privately owned company that has funding pending through an Irish Section 110-SPV private investment fund, utilizing a Qualifying Investor Fund (QIF). Ireland has become a popular jurisdiction for SPV's for structured finance transactions. Ireland's extensive double tax treaty network and onshore EU status make it a location of choice for expansion capital.

The US market demand for Hand Sanitizers is increasing for non-alcoholic products, according to GIA Research. "Private label brands continue to dominate the market. The US Hand Sanitizer sales are projected to reach US$226.3 million by 2018. Improving knowledge on Hand Care are presently driving the market for new sanitizers."

SHBAN is superior to alcohol gel because it is long-lasting up to 4 hours according to laboratory tests. If you have wondered why people who use alcohol gels still get colds and flu viruses it is because gels with 60% to 65% alcohol kill 99.9% of germs, but may not kill cold and flu viruses. It is dangerous to carry around alcohol gels with higher alcohol content because alcohol gels are a Class I fire hazard. Additionally, the Poison Control centers have reported over 22,000 poisonings from ingesting alcohol gels. Independent tests show SHBAN's active ingredient inhibits the Norovirus, Swine H1N1 and H5N1 Influenza A viruses.

SHBAN is gentle on hands. SHBAN can be used on a cotton swab in your nostrils. Studies indicate that 80% of viruses are inhaled. SHBAN is economical. One (1) ounce of SHBAN is equal six (6) ounces of alcohol gel. SHBAN is available online: www.shban.com.

Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties; actual results could differ materially from those expressed. The FDA has not evaluated the SHBAN statements above. SHBAN is not intended to diagnose, treat or cure any disease.


Contact:
Tom Wood
Sr. V.P. Sales
Phone: 972-274-5533



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES